Medical News

RSS

Study explains how breast milk fosters colonies of microbiotic flora in a newborn's intestinal tract

The benefits of breast milk have long been appreciated, but now scientists at Duke University Medical Center have described a unique property that makes mother's milk better than infant formula in protecting infants from infections and illnesses.

28 Aug 2012

FDA approves Gilead’s Stribild to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.

28 Aug 2012

America Stem Cell commences ASC-101 Phase I/II study in hematologic malignancies

America Stem Cell, Inc. announced today the initiation of a single-center study at The University of Texas MD Anderson Cancer Center evaluating ASC-101 in dual-umbilical cord transplantation in patients with hematologic malignancies.

28 Aug 2012

Short sleep duration linked to more aggressive breast cancers

Lack of sleep is linked to more aggressive breast cancers, according to new findings published in the August issue of Breast Cancer Research and Treatment by physician-scientists from University Hospitals Case Medical Center's Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University.

28 Aug 2012

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

28 Aug 2012

Neuralstem completes NSI-566 Phase I trial on amyotrophic lateral sclerosis

Neuralstem, Inc. announced the completion of the Phase I trial of its NSI-566 spinal cord neural stem cells for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), with the eighteenth patient treated.

28 Aug 2012

Roundup: Ga. AIDS Drug Assistance waiting list at zero; Mass. signs up for health law's disabled adults program

The state has eliminated a waiting list for a program that provides lifesaving medications to thousands of low-income, uninsured Georgians with HIV/AIDS more than two years after the list was first started. Established in July 2010, the wait list for Georgia's AIDS Drug Assistance Program rapidly ballooned to more than 1,600 -- at one time becoming the largest in the country. A spike in the need for the program was largely fueled by the economic downturn as people lost their jobs and health insurance.

28 Aug 2012

Chinese Medical Association, Copyright Clearance Center announce agreement

Copyright Clearance Center, Inc. (CCC), a not-for-profit organization and leading provider of licensing solutions, announces an agreement with the Chinese Medical Association (CMA), the largest medical journal publisher in China.

27 Aug 2012

Virtua achieves significant clinical milestone in the adoption of electronic health records

Today, Siemens Healthcare has announced that Virtua, a multi-hospital healthcare system, has achieved a significant clinical milestone in the adoption of electronic health records.

27 Aug 2012

Pristine Solutions acquires Eaton Scientific Systems

Pristine Solutions, Inc. is pleased to announce that the Company has completed the acquisition of Eaton Scientific Systems, Ltd., a biomedical product development company focused on women's health solutions.

27 Aug 2012

Blockade Medical's Barricade Coil System successfully treats patients with aneurysms

Blockade Medical announced today the first patients have been treated with the Barricade Coil System. Patients treated with the Barricade Coil System presented with diverse cerebral aneurysms.

27 Aug 2012

Women with severe aortic stenosis less likely to die following TAVI

Women with severe aortic stenosis are 40% less likely to die after transcatheter aortic valve implantation (TAVI) than men, reveals the latest data from the largest study to date of gender differences in outcomes after TAVI.

27 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

BioTime amends license agreement with University of Utah for HyStem technology

BioTime, Inc. announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products covered by the core patents underlying HyStem technology.

27 Aug 2012

Tris Pharma joins Perrigo to launch first ever store brand ER liquid cough/cold product

Perrigo Company and Tris Pharma, Inc. today announced the commercial launch of a major new store brand product. The new product is equivalent to Delsym extended–release oral liquid suspension containing dextromethorphan polistirex and will be marketed under major U.S. retailer and wholesalers' store brands or own label brands.

27 Aug 2012

Political cartoon: 'Opening Act?'

Kaiser Health News provides a fresh take on health policy developments with "Opening Act?" by John Deering.

27 Aug 2012

Diaverum plans to increase peritoneal dialysis use among patients with ESRD

Diaverum, one of the world's leading renal care providers, is planning to give more patients the possibility to be treated with peritoneal dialysis to increase their quality of life.

27 Aug 2012

IXYS board authorizes additional stock repurchase program

IXYS Corporation announced today that its Board of Directors has authorized an additional stock repurchase program of up to 1,000,000 shares of its common stock, or approximately 3% of the Company's approximately 31 million shares of common stock currently outstanding.

27 Aug 2012

Insulin glargine retards progression of atherosclerosis in high-risk people

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

27 Aug 2012

Academic Urology signs new contract with Independence Blue Cross

Academic Urology, the largest urology specialty medical group in Pennsylvania, announced today that it has signed a new contract with Independence Blue Cross (IBC).

27 Aug 2012